Animal Models Used in Cutaneous Pharmacology

Bouclier, Martine; Hensby, C.N.; Cavey, Daniel

doi:10.1007/978-1-4684-7902-7_6

Cited by 8 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is well known that COX/LOX inhibitors inhibit AAinduced ear edema and CGN-induced paw edema, while 5-LOX inhibitors and steroidal anti-inflammatory drugs such as prednisolone are active against PCA. 31,32) Pectolinarigenin and pectolinarin exhibited considerable inhibitory activity against these animal models, suggesting that they may also behave as COX/LOX inhibitors in vivo.…”

Section: Discussionmentioning

confidence: 99%

Anti-inflammatory Activity of Pectolinarigenin and Pectolinarin Isolated from Cirsium chanroenicum

Lim

Son

Chang

et al. 2008

Biological & Pharmaceutical Bulletin

110

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Anti-inflammatory Activity of Pectolinarigenin and Pectolinarin Isolated from Cirsium chanroenicum

Lim

Son

Chang

et al. 2008

Biological & Pharmaceutical Bulletin

110

View full text Add to dashboard Cite

“…The features of TGFPl regulation of injury response and healing may differ depending on the presence of distinct clearance mechanisms in each injury or, less likely, in each species. Inflammatory response differences between the two species may account for the distinct injury responses, even though the species appear to be similar in this regard (Bouclier et al, 1990). These differences serve to emphasize the critical importance of model selection and thorough comparison prior to direct extrapolation to human physiology.…”

Section: Discussionmentioning

confidence: 99%

Direct evidence for spatial and temporal regulation of transforming growth factor β1 expression during cutaneous wound healing

Kane

Hebda

Mansbridge

et al. 1991

Journal Cellular Physiology

217

125

View full text Add to dashboard Cite

The expression of transforming growth factor (TGF beta 1) protein in human and porcine skin has been analyzed by immunohistochemistry with two polyclonal antibodies (anti-CC and anti-LC) following cutaneous injury. The anti-LC antibody binds intracellular TGF beta 1 constitutively expressed in the nonproliferating, differentiated suprabasal keratinocytes in the epidermis of normal human skin, while the anti-CC antibody does not react with the form of TGF beta 1 present in normal skin as previously shown. TGF beta 1 may play a role in wound healing as suggested by its effect on multiple cell types in vitro and its acceleration of wound repair in animals. We have evaluated the natural expression and localization of TGF beta 1 protein in situ during initiation, progression, and resolution of the wound healing response in two models of cutaneous injury: the human suction blister and the dermatome excision of partial thickness procine skin. Anti-CC reactive TGF beta 1 in the epidermis is rapidly induced within 5 minutes following injury and progresses outward from the site of injury. The induction reflects a structural or conformational change in TGF beta 1 protein and can be blocked by the protease inhibitor leupeptin or by EDTA, suggesting a change in TGF beta 1 activity. One day post-injury anti-CC reactive TGF beta 1 is present in all epidermal keratinocytes adjacent to the wound including the basal cells. This corresponds temporally to the transient block of the basal keratinocyte mitotic burst following epithelial injury. Three to 4 days post-injury anti-CC reactive TGF beta 1 is localized around the suprabasal keratinocytes, in blood vessels, and in the papillary dermis in cellular infiltrates. The exclusion of TGF beta 1 from the rapidly proliferating basal cells and its extracellular association with suprabasal keratinocytes may represent physiological compartmentation of TGF beta 1 activity. Anti-CC staining is strong in the leading edge of the migrating epithelial sheet. The constitutive anti-LC reactivity with suprabasal keratinocytes seen in normal epidermis is neither relocalized nor abolished adjacent to the injury, but anti-LC staining is absent in the keratinocytes migrating within the wound. As the wound healing response resolves and the skin returns to normal, anti-CC reactive TGF beta 1 disappears while constitutive anti-LC reactive TGF beta 1 persists. Thus, changes in the structure or conformation of TGF beta 1, its localization, and perhaps its activity vary in a spatial and temporal manner following cutaneous injury and correlate with physiological changes during wound healing.

show abstract

“…Bouclier et al 21) investigated the histology of the dorsal skin of human beings, minipigs, rabbits, mice, rats and guinea pigs and found that minipigs had the most similar skin to human beings. Some studies 22,23) compared the skin permeability of mice, rats, rabbits, pigs, snakes, frogs and loaches in vitro, suggesting that pig skin had comparable permeability to human beings.…”

Section: Fig 3 Relative Recovery Of Lidocaine and Prilocaine Of Sixmentioning

confidence: 99%

Percutaneous Penetration Kinetics of Lidocaine and Prilocaine in Two Local Anesthetic Formulations Assessed by in Vivo Microdialysis in Pigs

Hui-lin

Chen

et al. 2007

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

The aim of this study was to characterize and compare the percutaneous penetration kinetics of lidocaine (L) and prilocaine (P) in two local anesthetic formulations by in vivo microdialysis coupled with HPLC. The microdialysis system for studying lidocaine and prilocaine was calibrated by a no-net-flux method in vitro and retrodialysis method in vivo, respectively. A dosage of 0.2 g/cm2 of an in-house P-L formulation (2.5% lidocaine and 2.5% prilocaine, methylcellulose-based) and commercially available Eutectic Mixture of Local Anesthesia (EMLA, 2.5% lidocaine and 2.5% prilocaine, carbopol-based) was separately but symmetrically applied in the dorsal region of pigs. Saline (0.9%, w/v) was perfused into the linear microdialysis probe at a flow rate of 1.5 microl/min. Dialysate was collected upon topical application up to 6 h at 20-min intervals and assessed by HPLC. The results demonstrated the area under the concentration-time curve (AUC(0-6 h)) of lidocaine and prilocaine in EMLA was 71.95+/-23.36 microg h/ml and 38.01+/-14.8 microg h/ml, respectively, in comparison to 167.11+/-56.12 microg h/ml and 87.02+/-30.38 microg h/ml in the P-L formulation. The maximal concentrations (Cmax) of lidocaine and prilocaine in the dermis were 29.2+/-9.08 microg/ml and 16.54+/-5.31 microg/ml in EMLA and 80.93+/-17.98 microg/ml and 43.69+/-12.87 microg/ml in the P-L formulation, respectively. This study indicates a well-calibrated microdialysis system can provide vital real-time information on percutaneous drug delivery and specifically a methylcellulose-based P-L formulation can increase percutaneous absorption of both lidocaine and prilocaine in pigs compared to carbopol-based EMLA.

show abstract

Animal Models Used in Cutaneous Pharmacology

Cited by 8 publications

References 40 publications

Anti-inflammatory Activity of Pectolinarigenin and Pectolinarin Isolated from Cirsium chanroenicum

Anti-inflammatory Activity of Pectolinarigenin and Pectolinarin Isolated from Cirsium chanroenicum

Direct evidence for spatial and temporal regulation of transforming growth factor β1 expression during cutaneous wound healing

Percutaneous Penetration Kinetics of Lidocaine and Prilocaine in Two Local Anesthetic Formulations Assessed by in Vivo Microdialysis in Pigs

Contact Info

Product

Resources

About